To date, only the cytotoxic activity of auriculasin has been studied in prostate cancer lines, where it induces ROS-mediated apoptotic cell death [80], suppresses angiogenesis [81] and sensitizes TRAIL-resistant primary prostate cancer cells to TRAIL-mediated apoptosis via the up-regulation of DR5 and downstream signaling pathways [82]. The gene discussed is TNFRSF10B; the disease is prostate cancer.